SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.50
−2.13%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
39.1x
EV/EBITDA
−180.6x
Market Cap
$2.38B
MomentumView details →
1D Return
−2.13%
YTD Return
+3.11%
RSI (14)
65.7
ValuationView details →
P/E (Fwd)
39.1x
EV/EBITDA
−180.6x
Market Cap
$2.38B
RSI (14)
65.7
MomentumView details →
1D Return
−2.13%
YTD Return
+3.11%
SummaryUpdated Jun 1, 2026
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company went public in 1997 and has evolved from a research-focused organization into a leading developer of RNA-targeted therapeutics and gene therapies for rare neuromuscular diseases. Sarepta achieved a major milestone in 2023 with the FDA approval of ELEVIDYS, the first gene therapy for Duchenne muscular dystrophy, transforming the company from a loss-making biotech into a profitable enterprise with over $1.9 billion in annual revenue as of 2024.
Similar companies
Latest newsMore news →
Sarepta Therapeutics shares rose 12% on Thursday, rebounding from July lows, as investors looked ahead to upcoming clinical data.8d agoSarepta Therapeutics appointed Michael Severino as its new CEO, effective July 28, succeeding Doug Ingram who is retiring.40d agoThe FDA accepted for filing the supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 submitted by Sarepta Therapeutics.67d ago